CA
NZ
UK
AU
IND
US
The company simultaneously announced that board member Tony Weisman is President and Chief Executive Officer, succeeding Mark Douglas. Weisman is a former Dunkin' U.S. chiefMarketingofficer and former CEO of Digitas. He said theBusinesshas strong product-market fit and needs operational rigor and a culture of …
Gross margin rose to 52.4%. Separately, the filing notes a favorable cost of sales adjustment of approximately USD 70 million over the nine months forTariffrefunds the company now considers probable after a Supreme Court ruling invalidated IEEPA tariffs. Selling, general and administrative expense fell …
Net premiums earned fell to USD 238.5 million, which the company attributes mainly to higher ceded premiums under reinsurance. Net premiumYielddropped to 31.2 basis points from 32.3. Losses incurred, net rose 119% to USD 23.9 million, a 10.0% loss ratio against 4.5%, as new …
Key HighlightsFirst-quarter fiscal 2027Net Incomewas USD 6.2 million, or USD 0.22 per diluted share, against a net loss of USD 3.7 million, or USD 0.13 per share, a year earlier.Adjusted net income, which excludes restructuring expense, was USD 6.4 million, or USD 0.23 per …
The prior-year quarter included a USD 115.0 million impairment tied to the Dalmatian field; there was none this year.Leaseoperating expenses fell to USD 149.2 million from USD 184.4 million on lower workover activity and insurance proceeds. Offsetting items were a USD 35.2 million rise …
For the fiscal year ended September 30, 2026, adjusted EBITDA rose 14.1% to USD 372.2 million, a 25.2% margin versus 22.8%. Net income was USD 221.9 million against USD 191.7 million.Operating Cash Flowrose 19.9% to USD 262.9 million, free cash flow reached USD 207.3 …
Net sales slipped 1.6% sequentially to USD 44.0 million, with Power Analog Solutions at USD 39.6 million and Power IC at USD 4.3 million. The operating loss widened to USD 12.9 million from USD 10.0 million in the second quarter. The non-GAAP adjusted loss, …
The Prenatal Health unit, which includes the Prequel, Foresight, SneakPeek and FirstGene tests, produced USD 39.3 million of revenue in the quarter, down 12%, with volume down 11% to 138,000 tests. By contrast, Cancer Care Continuum and Mental Health volume rose 3% to 239,000 …
Key HighlightsNiagen Bioscience (NASDAQ:NAGE) reported third-quarter net sales of USD 27.2 million, down 20% from USD 34.0 million a year earlier, with a net loss of USD 1.2 million againstNet Incomeof USD 4.6 million.Ingredients net sales fell 47% to USD 3.8 million from USD …
Key HighlightsNewAmsterdam Pharma (NASDAQ:NAMS) reported third-quarterRevenueof USD 19.2 million, versus USD 0.3 million a year earlier, driven by USD 18.3 million of license revenue and USD 0.8 million ofSupplyrevenue.The loss for the period narrowed to USD 17.4 million, or USD 0.14 per share, from …
Please wait processing your request...